Some 2seventy bio team members that have been working on the haemophilia A program will now be joining Novo Nordisk. Image Credit: Andrey_Popov/Shutterstock.

The European Commission has granted marketing authorisation to Sobi’s Altuvoct (efanesoctocog alfa) for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A.

The Commission also upheld the European Medicines Agency (EMA) recommendation for Altuvoct to retain its orphan drug designation. It grants a ten-year market exclusivity to the therapy, compared with the eight-year exclusivity that drugs usually receive as part of new drug authorisations.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The EU approval builds on the previous US approval for Altuvoct. In February, the US Food and Drug Administration (FDA) first approved the haemophilia A therapy for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery). The therapy is marketed as Altuviiio in the US.

Haemophilia A is a rare genetic disorder in which a person’s blood clotting ability is impaired because of a lack or total absence of a clotting factor, factor VIII. Altuvoct acts as a high-sustained recombinant factor VIII replacement therapy, which is administered once a week.

Haemophilia A is very rare and affects less than 1 in 10,000 people, as per the Canadian Hemophilia Society. It is also an X-chromosome-linked disorder that is very rare in females and disproportionately almost always affects males.

The European Commission approval was based on the data for adults and adolescents from the Phase III XTEND-1 (NCT04161495) [RM1] and paediatric patient trial data, from patients aged under 12 years, from XTEND-Kids (NCT04759131) trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Altuvoct is co-developed and commercialised by Sobi in partnership with Sanofi. Whilst Sobi has final development and commercialisation rights in Europe, North Africa, Russia and most Middle Eastern markets, Sanofi retains these rights in North America and all other regions in the world excluding the Sobi territory. The therapy is expected to generate $2.74bn in sales in 2030, as per GlobalData analysis.

GlobalData is the parent company of Pharmaceutical Technology.

Another high-profile treatment for haemophilia A is gene therapy, but its high cost can be a deterrent to adoption. In June 2023, the US FDA approved BioMarin’s gene therapy Roctavian (valoctocogene roxaparvovec-rvox) as a treatment for adults with haemophilia A. However, its eye-watering $2.9m price tag defied the expectations of the experts in the field, who predicted a price of approximately $1.95m.